W. Todd Penberthy, PhD

Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

Researchers have identified molecular markers in medullary thyroid cancer that were associated with response to vandetanib and the development of metastases.

Dual targeting of BRAF V600E–positive papillary thyroid carcinoma with the anti-BRAF V600E agent vemurafenib and the angiogenesis inhibitor sorafenib showed promising clinical activity.

A large survey of endocrinologists found wide variation in management strategies for thyroid nodules that were frequently misaligned with current guidelines, particularly for biopsies by fine-needle aspiration.